PMID- 22559854
OWN - NLM
STAT- MEDLINE
DCOM- 20120912
LR  - 20221207
IS  - 1936-2692 (Electronic)
IS  - 1088-0224 (Linking)
VI  - 18
IP  - 1 Suppl
DP  - 2012 Jan
TI  - Review of current and emerging therapies in type 2 diabetes mellitus.
PG  - S17-26
AB  - Significant advances in the treatment of type 2 diabetes mellitus (T2DM) include 
      the implementation of prevention efforts aimed at delaying progression of glucose 
      intolerance to overt diabetes mellitus (DM) and the development of new classes of 
      blood glucose-lowering medications to supplement existing therapies. While the 
      current management approach for T2DM continues to encompass traditional drugs 
      that focus on beta-cell failure and/or insulin resistance, newer agents that target 
      other defects (eg, incretin deficiency/resistance) are increasingly incorporated. 
      Furthermore, the effect of therapies on associated comorbidities (eg, 
      dyslipidemia, hypertension, obesity, hypercoagulability) has become an additional 
      therapeutic focus. This article provides a discussion of specific pharmacologic 
      agents, based on guidelines from the American Diabetes Association/European 
      Association for the Study of Diabetes and relevant clinical studies. An extensive 
      update on the newest drugs (eg, incretin-based therapies, amylin agonists) and 
      managed care aspects of diabetes care is also included.
FAU - Mazzola, Nissa
AU  - Mazzola N
AD  - College of Pharmacy and Allied Health Professions, St. John's University, Queens, 
      and North Shore University Hospital, Manhasset, NY, USA. mazzolan@stjohns.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Am J Manag Care
JT  - The American journal of managed care
JID - 9613960
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Sulfonylurea Compounds)
RN  - 0 (Thiazolidinediones)
MH  - Blood Glucose/*metabolism
MH  - Diabetes Mellitus, Type 2/*drug therapy/epidemiology/prevention & control
MH  - Disease Progression
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Insulin/therapeutic use
MH  - Sulfonylurea Compounds/therapeutic use
MH  - Thiazolidinediones/therapeutic use
MH  - United States/epidemiology
EDAT- 2012/05/18 06:00
MHDA- 2012/09/13 06:00
CRDT- 2012/05/08 06:00
PHST- 2012/05/08 06:00 [entrez]
PHST- 2012/05/18 06:00 [pubmed]
PHST- 2012/09/13 06:00 [medline]
AID - 46701 [pii]
PST - ppublish
SO  - Am J Manag Care. 2012 Jan;18(1 Suppl):S17-26.